Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (14921)	2/12/1998 7:30:00 PM
From: Flagrante Delictu	Read Replies (2) \| Respond to of 32384

Henry, << CNTO paid Roche $350 million for a cancer drug.>> That would amount to approximately $7.00 per share on LGND's approximately 50 million fully diluted shares. LGND announced at various bio conferences that the have 75 key IR targets, many of which are proprietary to LGND & another 2 dozen STAT's targets. One can see, in the light of this CNTO purchase , why DR has publicly stated that LGND has built substantial unrecognized {by Wall St.} value for its' shareholders. Makes one wonder if we sold too cheaply to LLY. Even if so, there could be plenty of unrecognized value left. Bernie